A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

(2011) S. Modi et al.   CLINICAL CANCER RESEARCH

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

(2011) David Siegel et al.   LEUKEMIA & LYMPHOMA

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Geldanamycin selectively targets the nascent form of ERBB3 for degradation

(2010) Candice S. Gerbin et al.   CELL STRESS & CHAPERONES

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

(2009) C. C. Leow et al.   MOLECULAR CANCER THERAPEUTICS

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas

(2008) Jeremy S. Abramson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

(2008) Dongweon Song et al.   MOLECULAR CANCER THERAPEUTICS